Biomarkers for bronchopulmonary dysplasia in the preterm infant

Lidys Rivera, Roopa Siddaiah, Christiana Oji-Mmuo, Gabriela R. Silveyra, Patricia Silveyra

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease of very-low-birth-weight (VLBW) preterm infants, associated with arrested lung development and a need for supplemental oxygen. Over the past few decades, the incidence of BPD has significantly raised as a result of improved survival of VLBW infants requiring mechanical ventilation. While early disease detection is critical to prevent chronic lung remodeling and complications later in life, BPD is often difficult to diagnose and prevent due to the lack of good biomarkers for identification of infants at risk, and overlapping symptoms with other diseases, such as pulmonary hypertension (PH). Due to the current lack of effective treatment available for BPD and PH, research is currently focused on primary prevention strategies, and identification of biomarkers for early diagnosis, that could also represent potential therapeutic targets. In addition, novel histopathological, biochemical, and molecular factors have been identified in the lung tissue and in biological fluids of BPD and PH patients that could associate with the disease phenotype. In this review, we provide an overview of biomarkers for pediatric BPD and PH that have been identified in clinical studies using various biological fluids. We also present a brief summary of the information available on current strategies and guidelines to prevent and diagnose BPD and PH, as well as their pathophysiology, risk factors, and experimental therapies currently available.

Original languageEnglish (US)
Article number33
JournalFrontiers in Pediatrics
Volume4
Issue numberMAR
DOIs
StatePublished - Mar 1 2016

Fingerprint

Bronchopulmonary Dysplasia
Premature Infants
Biomarkers
Pulmonary Hypertension
Very Low Birth Weight Infant
Lung
Early Diagnosis
Investigational Therapies
Primary Prevention
Artificial Respiration
Lung Diseases
Guidelines
Pediatrics
Oxygen
Phenotype
Survival
Incidence
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Rivera, Lidys ; Siddaiah, Roopa ; Oji-Mmuo, Christiana ; Silveyra, Gabriela R. ; Silveyra, Patricia. / Biomarkers for bronchopulmonary dysplasia in the preterm infant. In: Frontiers in Pediatrics. 2016 ; Vol. 4, No. MAR.
@article{552df7121b784d9ea238ea37bf45abfe,
title = "Biomarkers for bronchopulmonary dysplasia in the preterm infant",
abstract = "Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease of very-low-birth-weight (VLBW) preterm infants, associated with arrested lung development and a need for supplemental oxygen. Over the past few decades, the incidence of BPD has significantly raised as a result of improved survival of VLBW infants requiring mechanical ventilation. While early disease detection is critical to prevent chronic lung remodeling and complications later in life, BPD is often difficult to diagnose and prevent due to the lack of good biomarkers for identification of infants at risk, and overlapping symptoms with other diseases, such as pulmonary hypertension (PH). Due to the current lack of effective treatment available for BPD and PH, research is currently focused on primary prevention strategies, and identification of biomarkers for early diagnosis, that could also represent potential therapeutic targets. In addition, novel histopathological, biochemical, and molecular factors have been identified in the lung tissue and in biological fluids of BPD and PH patients that could associate with the disease phenotype. In this review, we provide an overview of biomarkers for pediatric BPD and PH that have been identified in clinical studies using various biological fluids. We also present a brief summary of the information available on current strategies and guidelines to prevent and diagnose BPD and PH, as well as their pathophysiology, risk factors, and experimental therapies currently available.",
author = "Lidys Rivera and Roopa Siddaiah and Christiana Oji-Mmuo and Silveyra, {Gabriela R.} and Patricia Silveyra",
year = "2016",
month = "3",
day = "1",
doi = "10.3389/fped.2016.00033",
language = "English (US)",
volume = "4",
journal = "Frontiers in Pediatrics",
issn = "2296-2360",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

Biomarkers for bronchopulmonary dysplasia in the preterm infant. / Rivera, Lidys; Siddaiah, Roopa; Oji-Mmuo, Christiana; Silveyra, Gabriela R.; Silveyra, Patricia.

In: Frontiers in Pediatrics, Vol. 4, No. MAR, 33, 01.03.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Biomarkers for bronchopulmonary dysplasia in the preterm infant

AU - Rivera, Lidys

AU - Siddaiah, Roopa

AU - Oji-Mmuo, Christiana

AU - Silveyra, Gabriela R.

AU - Silveyra, Patricia

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease of very-low-birth-weight (VLBW) preterm infants, associated with arrested lung development and a need for supplemental oxygen. Over the past few decades, the incidence of BPD has significantly raised as a result of improved survival of VLBW infants requiring mechanical ventilation. While early disease detection is critical to prevent chronic lung remodeling and complications later in life, BPD is often difficult to diagnose and prevent due to the lack of good biomarkers for identification of infants at risk, and overlapping symptoms with other diseases, such as pulmonary hypertension (PH). Due to the current lack of effective treatment available for BPD and PH, research is currently focused on primary prevention strategies, and identification of biomarkers for early diagnosis, that could also represent potential therapeutic targets. In addition, novel histopathological, biochemical, and molecular factors have been identified in the lung tissue and in biological fluids of BPD and PH patients that could associate with the disease phenotype. In this review, we provide an overview of biomarkers for pediatric BPD and PH that have been identified in clinical studies using various biological fluids. We also present a brief summary of the information available on current strategies and guidelines to prevent and diagnose BPD and PH, as well as their pathophysiology, risk factors, and experimental therapies currently available.

AB - Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease of very-low-birth-weight (VLBW) preterm infants, associated with arrested lung development and a need for supplemental oxygen. Over the past few decades, the incidence of BPD has significantly raised as a result of improved survival of VLBW infants requiring mechanical ventilation. While early disease detection is critical to prevent chronic lung remodeling and complications later in life, BPD is often difficult to diagnose and prevent due to the lack of good biomarkers for identification of infants at risk, and overlapping symptoms with other diseases, such as pulmonary hypertension (PH). Due to the current lack of effective treatment available for BPD and PH, research is currently focused on primary prevention strategies, and identification of biomarkers for early diagnosis, that could also represent potential therapeutic targets. In addition, novel histopathological, biochemical, and molecular factors have been identified in the lung tissue and in biological fluids of BPD and PH patients that could associate with the disease phenotype. In this review, we provide an overview of biomarkers for pediatric BPD and PH that have been identified in clinical studies using various biological fluids. We also present a brief summary of the information available on current strategies and guidelines to prevent and diagnose BPD and PH, as well as their pathophysiology, risk factors, and experimental therapies currently available.

UR - http://www.scopus.com/inward/record.url?scp=85002849885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002849885&partnerID=8YFLogxK

U2 - 10.3389/fped.2016.00033

DO - 10.3389/fped.2016.00033

M3 - Review article

VL - 4

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

SN - 2296-2360

IS - MAR

M1 - 33

ER -